Published guidance, NICE advice and quality standards | Guidance

Showing 381 to 390 of 797

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia	TA642	12 August 2020	12 August 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer	TA643	12 August 2020	12 August 2020
Entrectinib for treating NTRK fusion-positive solid tumours	TA644	12 August 2020	12 August 2020
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant	TA640	5 August 2020	5 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	TA638	1 July 2020	1 July 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	TA639	1 July 2020	1 July 2020
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)	TA634	30 June 2020	30 June 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	TA635	30 June 2020	30 June 2020
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)	TA636	30 June 2020	30 June 2020
Ranibizumab for treating diabetic retinopathy (terminated appraisal)	TA637	30 June 2020	30 June 2020